NEUROUROLOGY AND INCONTINENCE: Edited by John Heesakkers and Frank MartensTreatment of neurogenic lower urinary tract symptoms: main contributions from 2018 and 2019Abreu-Mendes, Pedroa,b; Cruz, Franciscoa,b,c; Martins-Silva, Carlosa,b,cAuthor Information aDepartment of Urology, Centro Hospitalar Universitário de São João bFaculty of Medicine of Porto ci3S Institute for Investigation and Innovation in Health, Porto, Portugal Correspondence to Francisco Cruz, MD, PhD, Faculty of Medicine, University of Porto, Alameda Hernani Monteiro, 4200-319 Porto, Portugal. Tel: +351 91 323 1123; e-mail: email@example.com Current Opinion in Urology: July 2020 - Volume 30 - Issue 4 - p 486-490 doi: 10.1097/MOU.0000000000000774 Buy Metrics Abstract Purpose of review This review aims to update the studies involving the treatment of lower urinary tract symptoms (LUTS) in neurogenic patients, published in the last two years. Recent findings Treatment of neurogenic LUTS (NLUTS) patients with β3 adrenoreceptor agonists was investigated in real-life conditions. A randomized controlled trial compared the efficacy of antimuscarinics versus onabotulinum toxin A in neurogenic patients. The use of desmopressin to treat nocturia in multiple sclerosis patients is also reported. The long-term treatment with BontA efficacy, its discontinuation, and possible strategies to maintain patients on treatment were also evaluated. Sacral neuromodulation and tibial nerve stimulation are continuously being evaluated in neurogenic patients, especially in the last years. Summary The management of urinary tract infections and vesical lithiasis, two common complications in NLUTS patients, and the management of both these patients was assessed in clinical trials. A trial evaluating the use of the anti-Nogo-A antibody after a spinal cord injury to facilitate neuronal rewiring and prevent or improve NLUTS was reported for the first time. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.